Pharma News

At a routine press conference on Tuesday, Chinese Foreign Ministry spokesperson Mao Ning stated that China is the country that shares the most COVID-19 data and research results with the international community. Mao pointed out that China has not only org

The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced on Tuesday the approval of a new drug developed by Merck for the treatment of a rare lung disease. This approval further solidifies the pharmaceutical company’s success in the pot

The National Health Commission (NHC) announced on Tuesday that China plans to address the gaps in mental health services between 2025 and 2027. This initiative aims to tackle the rising mental health issues, especially among children and adolescents. The

According to information published on the CDE (Center for Drug Evaluation) website on December 30, Sanofi’s market authorization application for its BTK inhibitor Rilzabrutinib has been officially accepted. Sanofi has conducted several clinical trials in

In 2024, China approved several new drugs, and more blockbuster drugs are expected to be launched in 2025, covering oncology, autoimmune diseases, rare diseases, and other therapeutic areas.

Since the construction of its first plant in 2013, Samsung Biologics established a joint venture with Biogen called Samsung Bioepis, focusing on the development and commercialization of biosimilars.

Recently, Johnson & Johnson (J&J) announced an agreement with Kaken Pharmaceutical of Japan to acquire the global exclusive rights (excluding Japan) to KP-723, a preclinical STAT6 inhibitor. Under the agreement, J&J will pay $30 million upfront, with pote

Merck recently announced that it has signed a global exclusive licensing agreement with Lixin Pharmaceuticals for an innovative PD-1/VEGF bispecific antibody named LM-299. According to the agreement, Merck will pay $588 million upfront, and Lixin Pharmace

The U.S. Food and Drug Administration (FDA) announced on Friday the approval of Bristol Myers Squibb's (BMS) injectable cancer drug Opdivo Qvantig. Opdivo, a PD-1 inhibitor, works by blocking the immune system’s natural inhibitory mechanisms, enhancing it

The U.S. Court of Appeals for the Second Circuit reinstated a whistleblower lawsuit against Swiss pharmaceutical giant Novartis on Friday. The lawsuit alleges that Novartis provided illegal kickbacks to doctors to boost sales of its multiple sclerosis dru

The CEO of Swiss pharmaceutical company Roche Holding AG (stock code: ROG.S), Thomas Schinecker, emphasized in an interview with the Swiss newspaper NZZ am Sonntag that the company currently has no layoff plans and that its business is in good shape.

The main content of this adjustment includes the establishment of four independent and collaborative divisions within the oncology business segment: the Lung Cancer Division, the Urology, Gynecology, and Gastrointestinal Oncology Division, the Breast Canc

On December 25, 2024, Eli Lilly’s glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist Tirzepatide (brand name: Mounjaro) was officially commercialized in the Chinese market. According to reports, several e-c

Merck will obtain global exclusive licensing rights for Hansoh’s oral small molecule GLP-1 receptor agonist HS-10535, while Hansoh will retain control of the drug in the Chinese market. The total amount of this collaboration is as high as $2 billion.

In August 2024, BMS terminated its partnership with Agenus for TIGIT/CD96 dual antibodies, leading to a $200 million loss. Similarly, collaborations such as the $3 billion investment with Immatics have also been terminated. These actions reflect Boerner's

On December 21, 2024, Jinhwa Enterprise (Group) Co., Ltd. released an official announcement stating that the company’s chairman, Xing Yajiang, received a “Notice of Investigation” (No. Zhengjian Investigation No. 0092024002) issued by the China Securities

In today’s market, companies must first secure market share and then focus on reducing overall costs through optimized production processes and lower operating expenses. Some argue that by maintaining a robust product line and using generic drugs to offse

On December 10, Realbio Gene Technology Co., Ltd. (688217.SH) announced that its chairman, general manager Xiong Hui, and vice general manager Xiong Jun were arrested on suspicion of fraud. Realbio’s main business involves in vitro diagnostic products and

Founded in 1995, By-Health introduced dietary supplements (VDS) to China in 2002 and successfully listed in 2010. Benefiting from its early investment in non-direct sales channels and leveraging the growth of chain pharmacies, the company transitioned suc

CagriSema is a combination drug composed of semaglutide and a long-acting amylin analog, cagrilintide. Given Novo Nordisk's success with semaglutide in diabetes and weight loss, CagriSema was highly anticipated as the next-generation product.